Hjem › Tripelnegativ brystkreft › South Carolina
Kliniske studier for Tripelnegativ brystkreft i South Carolina
9 studier for Tripelnegativ brystkreft søker deltakere på steder i South Carolina.
Byer i South Carolina
Offisiell studietekst (engelsk)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Medical University of South Carolina-Hollings Cancer Center ( Site 0016), Charleston
- St Francis Cancer Center ( Site 0093), Greenville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06966700Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- PRISMA Health/ITOR, Greenville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT05983432Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Medical University of South Carolina, Charleston
- St. Francis Cancer Center, Greenville
- Spartanburg Medical Center, Spartanburg
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT05633654A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
- Medical University of South Carolina Hollings Cancer Center,, Charleston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. aug. 2026 · NCT07743190A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Charleston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT07182149A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- St Francis Cancer Center, Greenville
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 10. aug. 2026 · NCT06926868NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
- Medical University of South Carolina, Charleston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT06845319Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Medical University of South Carolina, Charleston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. apr. 2026 · NCT04468061A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Greenville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jan. 2026 · NCT06999187Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.